Analyst Price Target is $1.88
▲ +482.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $1.88, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 482.66% upside from the last price of $0.32.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Aeglea BioTherapeutics. This rating has held steady since October 2021, when it changed from a Hold consensus rating.